



Tiaki Therapeutics announces plans to collaborate with Eisai to evaluate novel therapeutics for neuroinflammatory diseases

Cambridge, MA, March 29, 2019 - Tiaki Therapeutics today announces that Tiaki and Eisai Center for Genetics Guided Dementia Discovery (G2D2) will be collaborating to evaluate novel therapeutics for neuroinflammatory diseases utilizing Tiaki's novel, proprietary systems biology platform.

Under the collaboration, Tiaki will provide a spectrum of data on both genetic and chemical manipulation of its complex neuroinflammatory central nervous system (CNS) model system. These data provide biological insights into how chronic inflammation affects all CNS cell types, to support target validation and drug discovery decision-making. Both companies share a common interest in developing treatments to address these devastating diseases.

Barbara Tate, CEO of Tiaki said, "This collaboration is designed to unlock the value the two collaborators can bring together to develop novel treatments for dementia and neurodegenerative disease. The collaboration reinforces how the unique insights of Tiaki's innovative platform can be used to create a new generation of treatments for neurodegenerative diseases, and reflects our commitment, and the commitment of our investors, to bringing forward transformational medicines for dementia."

Tiaki Therapeutics

Tiaki is working to provide disease-modifying therapeutics that benefit patients with age-related dementias. Tiaki has developed a proprietary platform to reveal complex biological interactions of brain cells and drug targets to better enable the discovery and development of treatments for diseases of the CNS. In addition to collaborating with biotech and pharma partners, Tiaki is leveraging its platform technology to develop its own therapeutic programs. Tiaki was founded by the Dementia Discovery Fund ('DDF'), a mission-driven venture capital fund at the forefront of therapeutics for the treatment of dementias (<https://theddfund.com/>).